目的 探讨华蟾素胶囊联合贝伐珠单抗治疗晚期结直肠癌的临床疗效。方法 选取2015年1月—2017年1月在濮阳市安阳地区医院进行治疗的74例晚期结直肠癌患者，随机分为对照组（37例）和治疗组（37例）。对照组在化疗结束后第2天静脉滴注贝伐珠单抗注射液，5 mg/（kg·d），持续时间90 min以上，1次/2周。治疗组在对照组的基础上口服华蟾素胶囊，0.5 g/次，3次/d。两组患者均经过8周治疗。观察两组患者临床疗效，比较治疗前后两组患者生存质量改善情况、细胞因子水平、肿瘤标志物和不良反应情况。结果 治疗后，对照组客观缓解率（ORR）为37.84%，临床获益率（CBR）为70.27%，均分别显著低于治疗组的54.05%、89.19%，两组比较差异均具有统计学意义（P<0.05）。治疗后，对照组生存质量改善率为72.97%，明显低于治疗组的91.89%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组血清低氧诱导因子-1α（HIF-1α）、基质金属蛋白酶-2（MMP-2）、转化生子因子-β1（TGF-β1）、骨桥蛋白（OPN）水平均显著降低（P<0.05）；且治疗组患者细胞因子水平明显低于对照组（P<0.05）。治疗后，两组血清癌胚抗原（CEA）、糖蛋白199（CA199）水平均明显下降（P<0.05）；且治疗组比对照组下降更明显（P<0.05）。治疗过程中，治疗组不良反应发生率明显低于对照组患者，两组比较差异具有统计学意义（P<0.05）。结论 华蟾素胶囊联合贝伐珠单抗治疗晚期结直肠癌可有效改善患者生存质量，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Huachansu Capsules combined with bevacizumab in treatment of advanced colorectal cancer. Methods Patients (74 cases) with advanced colorectal cancer in Anyang District Hospital in Puyang City from January 2015 to January 2017 were randomly divided into control (37 cases) and treatment (37 cases) groups. Patients in the control group were iv administered with Bevacizumab Injection in 2nd day after chemotherapy, 5 mg/(kg·d), the duration time was more than 90 min, once every 2 weeks. Patients in the treatment group were po administered with Huachansu Capsules on the basis of the control group, 0.5 g/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy was evaluated, and the improvement of quality of life, cytokine levels, tumor markers and adverse reaction in two groups before and after treatment were compared. Results After treatment, the ORR and CBR in the control group were 37.84% and 70.27%, which were significantly lower than 54.05% and 89.19% in the treatment group, respectively, and there were differences between two groups (P < 0.05). After treatment, the improvement rate of quality of life in the control group was 72.97%, which was significantly lower than 91.89% in the treatment group, with significant difference between two groups (P < 0.05). After treatment, HIF-1α, MMP-2, TGF-β1, and OPN levels in two groups were significantly decreased (P < 0.05). And the cytokine levels in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the CEA and CA199 levels in two groups were significantly decreased (P < 0.05). And these tumor markers levels in the treatment group were significantly lower than those in the control group (P < 0.05). During the treatment, the incidence of adverse reactions in the treatment group was significantly lower than that in the control group, with significant difference between two groups (P < 0.05). Conclusion Huachansu Capsules combined with bevacizumab can effectively improve the quality of life in treatment of advanced colorectal cancer, which has a certain clinical application value.